Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats
Johnathan D. Keith, Mikayla Murphree-Terry, Gretchen Bollar, Ashley M. Oden, Ian H. Doty, Susan E. Birket · 2024
Read Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats by Johnathan D. Keith, Mikayla Murphree-Terry, Gretchen Bollar, Ashley M. Oden, Ian H. Doty, Susan E. Birket (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11536857.txt.
Description
Johnathan D Keith and co-authors test a cystic fibrosis drug in rats in this 2024 study. The drug, ivacaftor, boosts a faulty channel protein that causes the disease. New drug mixes have changed life for patients, yet lung bacteria still persist, and the reasons were unclear. The team used rats carrying a human version of the faulty gene to see how the drug affects infection over time.
Rats given the drug had fewer lung bacteria and fewer immune cells in airways in the early phase of infection. In the later, chronic phase those gains vanished, though mucus plugs were fewer and weight recovery was better. The channel itself worked at normal levels throughout. The authors conclude the drug helps rats tolerate infection rather than clear it.
Catalog record
| CREATOR | Johnathan D. Keith, Mikayla Murphree-Terry, Gretchen Bollar, Ashley M. Oden, Ian H. Doty, Susan E. Birket |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |